index - Epidemiology in dermatology and evaluation of therapeutics

DOCUMENTS

95

 

NOTICES

156

 

 

MOTS CLES

Biological Therapy Cardio-oncology BTK protein Anti-TNF Placebo Drug reaction Systematic review Biosimilar Pharmaceuticals Alcohol Burden Quality of life Epidemiology Bacterial rhinosinusitis Antibiotic misuse Apre-milast Immune-related adverse events Immune checkpoint inhibitors Drug survival Management COVID-19 Sipuleucel-T Autoimmunity Pharmacoepidemiology Glucocorticoids Angiotensin receptor blockers Meta-Analysis Dermatology Prostate cancer Cardiomyopathy Network meta-analysis Alitretinoin Primary adrenal insufficiency Intensive care Auto-immune hepatitis Arthritis Amyloidosis Vigibase® Antibiotic resistance Etanercept ArtThese Anticancer drugs Addiction Biologics Pregnancy Méta-Analyse Antibiotics Biological therapy Psoriatic arthritis Angiotensin-converting enzyme inhibitors Antimicrobials Anti-Bacterial Agents Acute Myeloid Leukaemia AML Apremilast Aging Spondyloarthritis Antimicrobial resistance Treatment Cardiotoxicity Ankylosing Pharmacovigilance Ankylosing spondylitis Biomarkers Adverse side effects Axial spondyloarthritis Atrial fibrillation Graft-versus-host disease Adolescent Accelerometer Anxiété Arrhythmia Stability Azathioprine Spondylitis Biologic therapy Cancer Biologic Antimicrobial Stewardship Ustekinumab Biologic drug Antimicrobiens Bacterial Anti-HCV Direct Acting Antivirals DAA Access to care Biomédicaments Atopic dermatitis Anxiety Auto-Diagnostic Endocrine toxicity ASDAS Autoimmune diseases Sacroiliitis Pharmaco-Épidémiologie Beta-lactam antibiotics Abus d'antibiotiques Infliximab Adalimumab Psoriasis Immunotherapy Ethics Albinism

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS